|
|
Article: Novavax Stock Jumps On Avian Flu Vaccine Success.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Shares of Novavax Inc. surged 31 percent on preclinical data showing that its influenza vaccine technology has proved effective against a feared strain of bird flu.
Scientists at the specialty biopharmaceutical company worked with government collaborators on the research, which demonstrated that a vaccine against the H9N2 avian flu strain, produced with Novavax's Virus-Like Particle (VLP) technology, effectively protected animals when challenged with live virus. Detailed results were published in the Aug. 15, 2005, online edition of Vaccine.
"This is a better way to present an antigen to the immune system," the company's ...